Clinical Trials Browser

Active not recruiting × Triple Negative Breast Neoplasms × Other solid neoplasm × Clear all

NCT04491942 2026-03-19

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Phase 1 Active not recruiting

126 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms